Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Bygrave · SciRah

Researcher profile · Semantic Scholar

C. Bygrave

Share profile

C. Bygrave — researcher profile on SciRah

h-index: 10
Works: 92
Citations: 483

Most-cited papers

Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients
R. Barnes, P. L. White, C. Bygrave, N. Evans +2 more
2008Journal of Clinical Pathology95 citations
Semantic Scholar
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy
G. Cook, A. J. Ashcroft, G. Pratt, R. Popat +12 more
2020British Journal of Haematology91 citations Open access
Semantic Scholar
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma
C. Bygrave, C. Pawlyn, F. Davies, Z. Craig +10 more
2020British Journal of Haematology44 citations Open access
Semantic Scholar
Risk of relapse of multiple myeloma following kidney transplantation
Sapna Shah, Maria Ibrahim, M. Delaney, S. Schey +3 more
2019Clinical Kidney Journal26 citations Open access
Semantic Scholar
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis
J. Khwaja, J. Bomsztyk, S. Mahmood, Brendan Wisniowski +17 more
2022Blood Cancer Journal21 citations Open access
Semantic Scholar
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
Kara-Louise Royle, A. Coulson, K. Ramasamy, D. Cairns +25 more
2022BMJ Open17 citations Open access
Semantic Scholar
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)
K. Yong, S. Hinsley, H. Auner, C. Bygrave +15 more
2021Haematologica16 citations Open access
Semantic Scholar
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study
M. Camilleri, M. Cuadrado, E. Phillips, W. Wilson +20 more
2021British Journal of Haematology13 citations Open access
Semantic Scholar
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
K. Yong, W. Wilson, R. de Tute, M. Camilleri +17 more
2022The Lancet Haematology12 citations Open access
Semantic Scholar
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
F. Djebbari, Alexandros Rampotas, G. Vallance, F. Panitsas +24 more
2022HemaSphere11 citations Open access
Semantic Scholar
Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper
M. Kaiser, V. Goh, Simon Stern, N. Spencer +8 more
2024British Journal of Haematology9 citations Open access
Semantic Scholar
Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper
M. Kaiser, G. Pratt, C. Bygrave, Kristian Bowles +2 more
2024British Journal of Haematology9 citations Open access
Semantic Scholar
Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis
J. Khwaja, J. Bomsztyk, M. Atta, C. Bygrave +15 more
2024British Journal of Haematology9 citations Open access
Semantic Scholar
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre UK retrospective analysis
A. McMillan, Supratik Basu, Kamaraj Karunanithi, Elizabeth Parkins +21 more
2023British Journal of Haematology9 citations
Semantic Scholar
Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study
K. Yong, Samantha Hinsley, H. Auner, Debbie Sherratt +14 more
20179 citations
Semantic Scholar
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
K. Yong, R. Popat, W. Wilson, Gavin Pang +18 more
2019Blood8 citations Open access
Semantic Scholar
Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
E. Searle, James Cavet, V. Campbell, S. Knapper +16 more
2023Blood7 citations Open access
Semantic Scholar
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience
N. Maouche, B. Kishore, M. Jenner, K. Boyd +13 more
2020Leukemia and Lymphoma7 citations
Semantic Scholar
Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation
K. Yong, Kara-Louise Royle, K. Ramasamy, C. Parrish +22 more
2022Blood6 citations Open access
Semantic Scholar
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
F. Djebbari, Alexandros Rampotas, G. Vallance, F. Panitsas +25 more
2022Hematology6 citations Open access
Semantic Scholar
Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study
K. Yong, S. Hinsley, Debbie Sherratt, J. Kendall +15 more
2018Blood6 citations Open access
Semantic Scholar
COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial
M. Camilleri, J. Sive, W. Wilson, Gavin Pang +14 more
2020British Journal of Haematology5 citations Open access
Semantic Scholar
Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
E. Searle, V. Campbell, C. Pawlyn, C. Bygrave +13 more
2024Blood4 citations
Semantic Scholar
Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).
K. Yong, M. Camilleri, W. Wilson, K. Ramasamy +16 more
2021Journal of Clinical Oncology4 citations
Semantic Scholar
Elranatamab for relapsed/refractory multiple myeloma – multi-centre real-world outcomes from the United Kingdom
O. Tomkins, Hannah Giles, Guy Pratt, B. Kishore +28 more
2025Blood3 citations
Semantic Scholar
Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
M. Rückert, Guillaume Azarias, M. Garg, C. Bygrave +12 more
2024Blood3 citations
Semantic Scholar
Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
R. Popat, C. Pawlyn, Robert Cicero, A. Hall +18 more
2024Blood3 citations
Semantic Scholar
RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients
K. Ramasamy, D. Cairns, Kara-Louise Royle, Robert Cicero +24 more
2023Blood3 citations Open access
Semantic Scholar
Daratumumab, Bortezomib and Dexamethasone (DVd) at First Relapse for Patients with Relapsed/ Refractory Multiple Myeloma (RRMM): A UK Myeloma Research Alliance (UK-MRA) Real-World Multicentre Analysis
A. McMillan, Supratik Basu, Kamaraj Karunanithi, Elizabeth Parkins +21 more
2021Blood3 citations Open access
Semantic Scholar
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy
A. Chari, M. Munder, K. Weisel, M. Jenner +17 more
2021Advances in Therapy3 citations Open access
Semantic Scholar
Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia
J. Zabkiewicz, M. Lazenby, G. Edwards, C. Bygrave +7 more
2020British Journal of Haematology3 citations Open access
Semantic Scholar
Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial
C. Bygrave, C. Pawlyn, F. Davies, D. Cairns +18 more
2018Blood3 citations Open access
Semantic Scholar
Secure: A Prospective Long-Term Observational Study in Patients with Monoclonal Gammopathy of Undetermined Significance
K. Ramasamy, Elizabeth Knight, Sulgi Byun, E. Heartin +36 more
2024Blood2 citations
Semantic Scholar
High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study
Dipal Mehta, L. Chiecchio, Martin F. Kaiser, S. Gooding +26 more
2023Blood2 citations Open access
Semantic Scholar
P863: AN OPEN-LABEL PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CCS1477 AS MONOTHERAPY AND IN COMBINATION WITH POMALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
E. Searle, J. Cavet, S. Knapper, C. Bygrave +14 more
2023HemaSphere2 citations Open access
Semantic Scholar
High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis
J. Khwaja, J. Bomsztyk, C. Bygrave, Adam Forbes +17 more
2023Blood2 citations Open access
Semantic Scholar
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial
S. Delimpasi, I. Špička, J. Butler, Don Stevens +5 more
2026British Journal of Haematology1 citations Open access
Semantic Scholar
Single-cell profiling of human bone marrow reveals multiple myeloma progression is accompanied by an increase in CD56bright bone marrow resident NK cells
Elise Rees, Isabella Sodi, K. Foster, L. Ainley +25 more
2025bioRxiv1 citations Open access
Semantic Scholar
Selinexor in combination with dexamethasone with or without bortezomib in heavily pretreated multiple myeloma: A case series
Nini Aung, Margaret Bowers, Gillian Brearton, Andrew Charlton +10 more
2024eJHaem1 citations Open access
Semantic Scholar
OA-19 Marrow Immune Features Are Most Informative of Early MRD Negative Treatment Response in Newly Diagnosed TE Patients: Insights from the UKMRA Phase 3 RADAR Study
Dipal Mehta, S. Henderson, Jasmine Rahman, Emma J. Lyon +21 more
2024Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
P-235 Isatuximab as Post-ASCT Therapy in MRDpositive Patients Augments CD8 Effector T Cell Differentiation: Insights from the UKMRA Phase 3 RADAR Study
Dipal Mehta, Jasmine Rahman, Emma J. Lyon, Elise Rees +20 more
2024Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)
Catherine S. Y. Lecat, Alan Chant, O. McCourt, David Meads +26 more
2023Blood1 citations Open access
Semantic Scholar
Isatuximab with Pomalidomide and Dexamethasone Provides Comparable Efficacy Outcomes in Frail Routine Care Myeloma Patients in a UK-Wide Cohort
Alexandros Rampotas, Alexandros Rampotas, G. Vallance, F. Panitsas +24 more
2022Blood1 citations Open access
Semantic Scholar
Efficacy Outcomes of Isatuximab with Pomalidomide and Dexamethasone Are Comparable to (ICARIA-MM) Trial Data: Initial Results of a UK-Wide Real-World Study of Relapsed Myeloma Patients
F. Djebbari, G. Vallance, Nanda Basker, F. Panitsas +24 more
2021Blood1 citations Open access
Semantic Scholar
PA-114 Co-opting the BAFF-APRIL Pathway in Smouldering Myeloma (SMM) to Fuel Disease Progression
Elise Rees, A. Mirandari, Emma J. Lyon, L. Ainley +20 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PA-235 Immune Determinants of MRD Response in Ultra-High-Risk Multiple Myeloma: Analysis from the UK MRA RADAR Study
Elise Rees, Conor Garrod-Ketchley, Emma J. Lyon, Marcela Vazquez Bermejo +21 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PA-294 Marrow Immune Features Are Most Informative of Sustained MRD Negative Response in Newly Diagnosed Standard Risk TE Patients: Findings From the UK MRA RADAR Study
Emma J. Lyon, S. Henderson, Elise Rees, A. Mirandari +20 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
OA-25 Evaluation of a Vision-Related Anamnestic Tool (VRAT) to Guide Belantamab Mafodotin Dosing With Bortezomib and Dexamethasone for Multiple Myeloma: Interim Results From the UKMRA ProMMise D Trial
R. Popat, Alexandra G. Welsh, A. Hall, C. Bygrave +19 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PA-509 Trial in Progress: Isatuximab and Iberdomide as Immunotherapy for High-Risk Smouldering Myeloma – The UK Myeloma Research Alliance MODIFY Clinical Trial
Dean Smith, Simon Hallam, C. Bygrave, Kamaraj Karunanithi +11 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
PA-208 Function Tracks Disease, Psychology Tracks Diagnosis: Dissociable Patient-Reported Burden in Smouldering Myeloma: Initial Report from the UK MRA COSMOS Study
Daniel Hughes, Catherine S. Y. Lecat, L. Ainley, Rethina Shritharan +21 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Popat×19
Invite
R. Popat — researcher profile on SciRah
K. Ramasamy×19
Invite
K. Ramasamy — researcher profile on SciRah
R. Owen×15
Invite
R. Owen — researcher profile on SciRah
R. de Tute×15
Invite
R. de Tute — researcher profile on SciRah

×14

Invite

J. Sive — researcher profile on SciRah

Invite

K. Yong — researcher profile on SciRah

Invite

M. Jenner — researcher profile on SciRah

Kara-Louise Royle×9

Invite

Kara-Louise Royle — researcher profile on SciRah

Invite

Guy Pratt — researcher profile on SciRah

Invite

G. Cook — researcher profile on SciRah

Invite

M. Streetly — researcher profile on SciRah

Lorna Barnard×8

Invite

Lorna Barnard — researcher profile on SciRah